Peptides are exploding in popularity—but the rules around them are anything but clear.

In Episode 104, we unpack the growing clash between RFK Jr. and the FDA over peptide regulation, the rise of the gray market, and what this means for safety, access, and the future of clinical innovation.

This isn’t just a policy debate—it’s a turning point for the entire wellness industry.